Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA7 | P43166 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | TYR | P14679 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL910590 | 0.80 | CES2 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6895905 | 0.76 | TRPA1 (0.52) | ALDH1A1LMNAALOX15HSD17B10HTT | |
| SCHEMBL5160436 | 0.76 | ALOX15 (0.50) | CA12CA9CES2ALDH1A1CYP2C9 | |
| SCHEMBL5163990 | 0.76 | HSD17B10 (0.50) | CA1CA2ALOX5ALDH1A1LMNA | |
| SCHEMBL28790418 | 0.76 | ACHE (0.43) | NR1H3CA12CA9ALDH1A1LMNA | |
| SCHEMBL4259409 | 0.76 | CYP1A2 (0.45) | CA9CYP2C9ALOX15HSD17B10MIF | |
| SCHEMBL358267 | 0.75 | ESR1 (0.44) | NR1H3CA12CA1CA2CA7 | |
| SCHEMBL14597455 | 0.75 | NR1H3 (0.45) | NR1H3CA12CA1CA2CA7 | |
| SCHEMBL1267040 | 0.75 | ESR2 (0.44) | CA12CA2CA9CA14MIF | |
| SCHEMBL29771448 | 0.75 | ESR1 (0.44) | NR1H3CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3929207-B1 | PEPTIDE FTTFTVT FOR USE IN TREATING FIBROSIS | UNIV TEXAS (US) | 2024-07-17 | — | — | EP | claimed |
| EP-3929207-A1 | INHIBITION OF PULMONARY FIBROSIS WITH NUTLIN-3A AND PEPTIDES | Board of Regents, The University of Texas System (US) | 2021-12-29 | — | — | EP | claimed |
| US-20180086791-A1 | INHIBITION OF PULMONARY FIBROSIS WITH NUTLIN-3A AND PEPTIDES | UNIV TEXAS (US) | 2018-03-29 | — | — | US | claimed |
| EP-0983259-B1 | TOCOPHEROL ESTERS AND THEIR COSMETIC AND PHARMACEUTICAL USES | LVMH RECH (FR) | 2002-08-07 | — | — | EP | claimed |
| US-6136851-A | SKIN DISORDERS | LVMH RECHERCHE (FR) | 2000-10-24 | — | — | US | claimed |
| EP-0983259-A1 | TOCOPHEROL ESTERS AND THEIR COSMETIC AND PHARMACEUTICAL USES | LVMH RECHERCHE (FR) | 2000-03-08 | — | — | EP | claimed |
| WO-1998051679-A1 | TOCOPHEROL ESTERS AND THEIR COSMETIC AND PHARMACEUTICAL USES | LVMH RECHERCHE (FR) | 1998-11-19 | — | — | WO | claimed |
| WO-1997014685-A1 | PYRIMIDINE DERIVATIVES | GYÓGYSZERKUTATÓ INTÉZET KFT (HU) | 1997-04-24 | — | — | WO | claimed |
| EP-3929207-B1 | PEPTIDE FTTFTVT FOR USE IN TREATING FIBROSIS | UNIV TEXAS (US) | 2024-07-17 | — | — | EP | disclosed |
| US-20240067713-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CHRONIC LUNG DISEASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240059736-A1 | INHIBITION OF PULMONARY FIBROSIS WITH NUTLIN-3A AND PEPTIDES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-02-22 | — | — | US | disclosed |
| US-11905336-B2 | Modified peptide fragments of CAV-1 protein and the use thereof in the treatment of fibrosis | LUNG THERAPEUTICS, INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-20240018186-A1 | MODIFIED PEPTIDE FRAGMENTS OF CAV-1 PROTEIN AND THE USE THEREOF IN THE TREATMENT OF FIBROSIS | LUNG THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2024015857-A2 | MODIFIED CAVEOLIN-1 PEPTIDE FORMULATIONS AND METHODS OF MANUFACTURING AND USE THEREOF | LUNG THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | disclosed |
| US-5464833-A | Anticarcinogenic agents, antiretrovirus agents or autoimmune diseases | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-11-07 | — | — | US | disclosed |
| EP-0623598-A1 | APOPTOSIS REGULATOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-09 | — | — | EP | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
| US-4760064-A | Cardiotonic agent | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-07-26 | — | — | US | disclosed |
| EP-0187322-A1 | Carbostyril compounds, compositions containing same and processes for preparing same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086791-A1 | INHIBITION OF PULMONARY FIBROSIS WITH NUTLIN-3A AND PEPTIDES | IGFBP4, FN1, MDM2 | NR1H3 3714/4885CA12 4671/4885CA1 4237/4885 |
| US-20240059736-A1 | INHIBITION OF PULMONARY FIBROSIS WITH NUTLIN-3A AND PEPTIDES | IGFBP4, FN1, MDM2 | NR1H3 3714/4885CA12 4671/4885CA1 4237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.